Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of ipilimumab + fotemustine in unresectable or metastatic malignant melanoma
2010-019356-50Phase 2Completed
- Sponsor
- Fondazione NIBIT
- Start
- Apr 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ipilimumab and fotemustine in melanoma, sponsored by Fondazione NIBIT. Primary endpoint: immune-related disease control rate. Started Apr 2010; status: completed.
02
Drugs
ipilimumabfotemustine
03
Conditions
melanoma
Beyond the preview
Go deeper on 2010-019356-50.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019356-50.